News & Updates

Findings from a phase II trial demonstrate the potential of transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT) for men with metastatic (M1) prostate cancer who are on androgen receptor pathway inhibitors (ARPI).

A combination regimen comprising trifluridine/tipiracil (FTD/TPI) and bevacizumab demonstrates favourable efficacy and safety in individuals with metastatic colorectal cancer (mCRC) in the real-world BeTAS study presented at ASCO GI 2025.

In the real-world treatment of older adults with inflammatory bowel disease (IBD), the cardiovascular safety of ustekinumab is similar to that of vedolizumab, with no significant difference in the risk of major adverse cardiovascular events (MACE). However, ustekinumab is associated with a reduced risk of all-cause mortality.